The introduction of targeted therapies has greatly revolutionized the overall paradigm of cancer treatment.
Global PDGFR Inhibitors Market, Drug Sales and Clinical Trials Insight 2026 Report Analysis and Data Highlights:
- Research Methodology
- Global and Regional Market Analysis
- Global PDGFR Inhibitors Market Opportunity Assessment: > USD 4 Billion
- Market and Drug Sales Insight 2020 Till 2026
- Approved Drug In Market: 2 (Qinlock and Ayvakit)
- Approved PGDFR Drug Patent, Price and Sales insight 2020 Till 2026
- Future market Assessment By Indication and Region Till 2026
- Ongoing Clinical Trials Assessment by Status, Phase and Region
- Key Market Dynamics
- Competitor Landscape
Download Report:
The introduction of targeted therapies has greatly revolutionized the overall paradigm of cancer treatment. Owing to their advantages in terms of specificity and efficacy compared to traditional cancer drugs, targeted cancer therapies have gained considerable momentum in market. Amid all targeted therapies, small molecule inhibitor drugs have gained considerable interest attributing to their small size and ability to cross blood brain barrier. These drugs work by inhibiting the genes or proteins which are essential for the progression of cancer.
The advancement in the field of cancer biology has led to identification of platelet derived growth factor receptor (PDGFR). Studies have shown that platelet derived growth factor receptor (PDGFR) acts as one the key regulator for the regulation of normal cell growth and division and hence it is considered as potential therapeutic target for the treatment of several cancers. To date, three PDGFR inhibitors have been approved including Larturvo, Ayvakit, and Qinlock. However, Larturvo has been discontinued from market as it failed to improve overall survival in phase-III studies.
Ayvakit (Avapritinib) is a selective molecule inhibitor of KIT and PDGFRA activation loop mutants which was developed by Blueprint Medicines Corporation. It is the first tyrosine kinase inhibitor which has been approved for the management of gastrointestinal stromal tumor with the PDGFRA D842V mutation. The drug belongs to the class of competitive ATP binding inhibitor which is designed specifically to interact with the active conformation (type I kinase inhibitor), unlike the early type II kinase inhibitors that only bind to the inactive conformation. In the same year, Ripretinib sold under brand name Qinlcok has also gained approval. The drug is developed by Deciphera Pharmaceuticals and is indicated for the treatment of gastrointestinal tumors. The introduction of these two PDGFR inhibitors has spurred the research and development activities in this domain by demonstrating encouraging response in the market.
In addition to currently available PDGFR inhibitors, several other PDGFR inhibitors are current present in development. The pipeline of PDGFR inhibitors is highly crowded and consists of several potential candidates including Crenolanib, Tovetumab, Seralutinib, ARRY-768, CP-673451, and MTLH001. Apart from cancer, several ongoing clinical trials are also evaluating the role of novel PDGFR inhibitor in other therapeutic indications, such as Pulmonary Arterial Hypertension (PAH). These drugs are majorly present in phase-I/II clinical trials, suggesting that the market will see rapid influx of novel PDGFR inhibitors in forthcoming years. In addition, pharmaceutical giants have adopted several novel strategies including alliance, collaboration or partnerships which aid in securing their position worldwide.
Increasing incidences of cancers such as breast cancer, lung cancer, colorectal cancer, gastrointestinal cancer and among others is driving growth of PDGFR inhibitor drugs market. Moreover, growing funding on cancer research, rising insurance coverage and rise in number of new targeted anti-cancer drugs is again expected to supports the growth of market in forthcoming years. Apart from this, the government of different countries and private organizations are investing heavily in these research institutes, which are boosting the development of novel PDGFR inhibitor in the market. As per our report findings, the global PDGFR inhibitor market will surpass US$ XX Billion by 2028.
The report provides comprehensive analysis on the commercial information of available PDGFR inhibitor including patent, pricing, dosage, and sales analysis. The report includes estimation of the market size and analyses of global market trends, with data from 2019, 2020, and 2021 and projections of compound annual growth rates (CAGRs) through 2028. The report also identifies market drivers, restraints and other forces impacting the global market. The major companies mentioned in the report are AstraZeneca. Clovis Oncology, Bayer, Blueprint Medicine, Zai Lab, Pfizer, Gilead Sciences, Deciphera Pharmaceuticals, and several others.
Contact:
Neeraj Chawla
Research Head
Kuick Research
neeraj@kuickresearch.com
+91-9810410366